The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures

Inclusion Criteria: * Patients who are at least 18 years of age and who have closed epiphyses. * Patients of both genders and all races. * Patients with Jones fractures of the fifth metatarsal less than 2 weeks prior to presenting for clinical evaluation. * Patients with a history of an acute injury and an acute Jones fracture defined by Torg et al as a fracture line with sharp margins without widening, absence of intramedullary sclerosis, and minimal or no cortical hypertrophy or evidence of periosteal changes due to chronic stress. * Patients with either no prodromal symptoms or prodromal symptoms present less than 2 weeks. * Patients with a baseline visual analog scale (VAS) pain score ≤ 20 (100mm scale) for the fifth metatarsal, with the foot at rest and not bearing weight. * Patients who are in good general health and who have physical examinations that either are within normal limits or are clinically non-significant as determined by the investigator. * Patients with laboratory evaluations that either are within normal limits or are clinically non-significant as determined by the investigator. * Patients who have voluntarily signed informed consent forms, including HIPAA Authorization. Exclusion Criteria: * Patients who are younger than 18 years of age or patients who are 18 years of age or older with open epiphyses. * Patients with Jones fractures of the fifth metatarsal greater than 2 weeks prior to presenting for clinical evaluation. * Patients with tuberosity avulsion fractures or fifth metatarsal shaft fractures. * Patients with prior fifth metatarsal fracture(s). * Patients with prodromal symptoms present for more than 2 weeks. * Patients with a nonunion or delayed union as defined by the radiographic criteria described by Torg et al. * Patients who are allergic to any of the individual active ingredients in teriparatide or related compounds. * Patients with chronic rheumatologic disease, ankylosing spondylitis or other inflammatory arthropathy. * Patients with associated injuries considered by the investigator as to likely interfere with evaluation of the study drug. * Patients with a present condition or history of any clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematologic, endocrine, neurologic, psychiatric, connective tissue, respiratory or other medical disorders. * Patients with Worker's Compensation claim(s) under dispute or mediation. * Patients with history of drug or alcohol abuse. * Patients who are pregnant or lactating. * Patients who are considered by the investigator for any reason to be an unsuitable candidate for receipt of the study drug. * Patients who are unwilling or unable to follow the follow-up evaluation schedules. * Patients who refuse to voluntarily sign the informed consent form.